Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Investors

Investors

Eshelman Ventures LLC

Fred Eshelman is a founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies.  Dr. Eshelman typically serves on the board of portfolio companies.  Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests.

After PPD he served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals (FURX, NASDAQ), a company which licensed and rapidly developed new medicines.  Furiex was sold to Forest Labs/Actavis in July, 2014.

His career has also included positions as Senior Vice President (development) and board member of the former Glaxo, Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals.

Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, USA, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With four funds, the firm has more than $200 million under management.

Intersouth Partners

Intersouth Partners is one of the most active and experienced venture funds in the Southeast, having invested in more than 100 private companies over the last two decades. Founded in 1985, Intersouth manages $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast. Based in Durham, North Carolina, USA, Intersouth Partners seeks a broad range of investment opportunities in the technology and life sciences sectors.

Lilly Ventures

Lilly Ventures, a stand-alone venture capital firm with its roots in the scientific tradition of Eli Lilly and Company, seeks to invest in great companies with compelling life science innovations and outstanding management teams in North America and Europe. The firm actively partners with management teams and co-investors of our portfolio companies at the seed, early and expansion stages. Lilly Ventures targets investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline that can have a meaningful impact on patient outcomes. Lilly Ventures is located in Indianapolis, Indiana, USA.

Lurie Holdings

Lurie Holdings, Inc. manages investments for Ann Lurie and various Lurie family trusts for which Ms. Lurie is trustee. Lurie Holdings, LLC is based in Chicago, Illinois, USA.

Novartis Venture Fund

Established in 1996, the Novartis Venture Fund (NVF) currently manages over $ 1.1 billion in committed capital and is invested in more than 45 private companies. The NVF invests in innovative life sciences companies for patient benefit creating attractive returns for entrepreneurs and investors.  The NVF is located in Basel, Switzerland and Cambridge, Massachusetts, USA.